Search Results for: liver cancer

The power of CAR-T cell therapy

The CAR – T Apheresis team with Professor Anastasios Karadimitris

To mark Blood Cancer Awareness Month, Dr Lucy Cook, Consultant Haematologist at Imperial College Healthcare NHS Trust and Honorary Senior Clinical Lecturer from the Department of Immunology and Inflammation, shares how CAR-T cell therapy is transforming blood cancer treatment for patients.


September is Blood Cancer Awareness month, a time dedicated to raising awareness of blood cancers, which often don’t receive the same recognition as other types of cancer types. According to the charity Blood Cancer UK, over half of British adults cannot name a single blood cancer symptom. With over 100 different types of blood cancer, patients often know the name of their specific diagnosis (such as leukaemia, lymphoma, myeloma, myelodysplastic syndrome, CML etc.) but may not realise that these are all forms of blood cancer. Collectively, blood cancers are the third most common group of cancers. Raising awareness among both the public and health care professionals is critical to improving early detection and diagnosis.

At Imperial College London and Imperial College Healthcare NHS Trust, September gives us the opportunity to reflect on the progress made since last year’s Blood Cancer Awareness Month.  One of the most exciting aspects has been the delivery of CAR-T cell therapy for lymphomas (a type of blood cancer that affects white blood cells) and acute lymphoblastic leukemia (a rare type of cancer that affects the blood and bone marrow). This year, the National Institute for Health and Care Excellence (NICE) also approved several new bispecific antibody therapies (BITEs) for lymphoma and myeloma (a type of cancer that develops from plasma cells in the bone marrow). BITEs are special proteins designed to help the immune system fight cancer. CAR-T and BITEs are a new wave of therapies, that harness the immune system to kill the cancer cells, rather than relying on conventional chemotherapy.  Following successful clinical trials, these therapies are now broadly approved for use in patients who have not responded to chemotherapy, offering potentially curative treatments for patients who previously faced poor prognoses. Clinical trials for CAR-T cell therapy are in progress for multiple myeloma, which is really exciting, offering hope for longer remissions for patients with a cancer subtype where no curative treatments currently exist.

(more…)

World No Tobacco Day – how to get where we need to be?

Nick HopkinsonThe path to a smokefree generation demands decisive action and innovative strategies. To mark World No Tobacco Day, Professor Nick Hopkinson from the National Heart & Lung Institute (NHLI) offers his insights, drawing on years of dedicated research to suggest ways in which we can achieve this. 


Smoking is the leading preventable cause of premature disability and death; two out of three people who continue to smoke will die from a smoking-related disease. Ending this requires two things: First, ensuring that people don’t start to smoke in the first place; and second, supporting the more than six million people in the UK who still smoke to quit.

‘Stopping the start’ involves making smoking less appealing,less affordable, and less available to children and young people. A key step to creating a smokefree generation will be steadily raising the age of sale, ensuring that tobacco products can never legally be sold to people born on or after 1 January 2009. The General Election has paused the progress of this legislation, but the policy has enjoyed cross-party support, so is almost certain to become law. We can be confident that it will be effective – youth smoking rates fell when the age of sale in the UK was increased from 16 to 18 in 2007, and similarly where it has been increased to 21 in the US. The year-on-year increase will also prevent the tobacco industry from addicting people later in life.

(more…)

From Britpop to breakthroughs: Reflecting on 30 years of HIV testing and treatment

Born on what would eventually be recognized as World AIDS Day in the 1970s, Dr Mike Emerson, now affiliated with the National Heart and Lung Institute, relocated to vibrant London during the early 1990s amidst the fervour of the Britpop era. In the backdrop of Blur and Pulp melodies, 1990s London faced the AIDS crisis. Three decades later, he is at the helm of a team investigating cardiovascular ailments in people with HIV. In this piece, Dr Emerson reflects on the advancements in HIV diagnosis and therapy, and reiterates the ongoing importance of  National HIV Testing Week. 


I was born on what was to become World AIDS day way back in the 1970s, and moved to the big smoke in the early 90s. London was exploding with Britpop excitement, and in the absence of mobile tech, we went out every night to the sounds of Blur and Pulp. 90s London was also the epicentre of the UK’s bit of the global AIDS crisis. People in their early 20s, as I was, were dying (of ignorance the government told us). I quickly learnt not to hold birthday celebrations in Soho; celebrating and mourning young friends and sons don’t mix well. Exactly 30 years later, I lead a team investigating cardiovascular disease as people live with HIV for decades and succumb to the diseases of old age. This week is HIV testing week, so it’s a good time to reflect on how far we have come and remind ourselves of the importance of HIV testing. 

Back in 1981, a couple of obscure articles noted incidences of fatal pneumonia and rare skin cancers in otherwise healthy young American men. Oddly, these men were all gay. Within months, there was an explosion of terrifying fatal illness amongst the gay communities of New York, San Francisco and, not far behind, London. People became infected with HIV following blood transfusions, and babies were born with the condition and died. When HIV tests became available, the prospect of one was terrifying, involving a week-long wait for results and a recommendation to take a friend when results were due to be delivered. 

(more…)

Do we need such a devastating global pandemic to raise the profile of research?


On Clinical Trials Day, Fran Husson discusses how receiving treatment for Acute Myeloblastic Leukaemia made her aware of the value and impact of research.


It is impossible, as a patient, not to think “vaccination” when asked to engage in some reflection about “Research”.  Vaccines would not have been created so swiftly to combat Sars-CoV-2 if strong and well established multi-disciplinary cohorts of researchers, within prominent academic institutions, had not been in place to mastermind clinical trials and produce an effective immunisation response to the pandemic.

This begs the question of Patient and Public awareness of research, whether for clinical purposes or service delivery of health and social care.  Do we need such a devastating global pandemic to raise the profile of research?

In my case, a late diagnosis of Acute Myeloblastic Leukaemia provided the lightning bolt to make me aware of research. Hospitalised in isolation for ten months, under round-the-clock treatment from clinicians who also involved me in different clinical research projects, I could not but appreciate the full value and impact of research. (more…)

Radiation and human health – separating scientific facts from urban myths

Professor Gerry Thomas
This festive period Three Wise Women from the Faculty of Medicine will be giving us the gift of wisdom.

Our first is Professor Gerry Thomas, a leading authority on the health impacts of radiation, who tells us why we should focus on the facts.


I was born in the 1960s and grew up believing that the word ‘radiation’ meant something that was infinitely dangerous. Back then, we were led to believe that nuclear weapons would lead to the extinction of our species, and that to be bitten by a radioactive spider would confer supernatural powers! I was therefore sceptical about the use of nuclear power. It wasn’t until 1992, when I started to study the health effects of the accident at the Chernobyl nuclear power station in 1986, that I began to question whether my understanding of the health effects of radiation came more from science fiction than scientific fact. (more…)

A smoke-free country: how will we get there?

The Government recently announced plans to create a smoke-free society by 2030 – Dr Nick Hopkinson outlines some of the steps towards achieving this ambition.


Tobacco smoking remains a huge public health issue. Although population smoking rates continue to fall – now down to 14.4% of adults – smoking is still responsible for around 100,000 deaths per year in the UK, and for around half the difference in life expectancy between rich and poor. Smoking rates are high in areas of deprivation, in people with mental health problems and among people who identify as LGBT.

The Government’s recent green paper, Advancing our health: prevention in the 2020’s, although in many areas light on detail, funding, delivery and ambition, does set out some important markers on smoking and some potentially interesting developments around funding tobacco control. (more…)

Providing medical care during a mission to Mars: science or fiction?

50 years on from the historic Apollo Moon landings, the race to Mars is on. With this in mind, Dr Matthieu Komorowski is examining how to provide medical care during long-flight space missions.


“The extension of life beyond Earth is the single most important thing we can do as a species” once said Elon Musk, the CEO of SpaceX.

Many other eminent minds have expressed a similar vision, including Stephen Hawking, Carl Sagan, Konstantin Tsiolkovsky, Buzz Aldrin and so on. They all argue that there are too many risks that can befall life on a single planet. As nicely put by Robert Heinlein: “The Earth is just too small and fragile a basket for the human race to keep all its eggs in.”

Could we possibly support such a bold idea ourselves? Is it more important to colonise Mars than to: improve our earthly existence, achieve equality and peace for all humans, protect our delicate environment, or cure diseases and world hunger? The argument is that these endeavours, as charitable as they are, all become meaningless if the following day life is wiped out from the face of the planet by a giant asteroid or a superbug. The long-term vision of space colonisation spans way beyond the blink of our existence and space advocates insist that in the long run, there are only two possible avenues: expansion into space or extinction! (more…)

Leading from the front: what can academia learn from the Army

Army leadership

Former British Army officer and current PhD student, Nadia Soliman, discusses the importance of leadership in academia and the lessons we can learn from the Army’s renowned leadership programmes. 


In my opinion the Army and academic institutions are very similar: both are organisations that work globally, across cultures and are dependent upon their people doing remarkable things to tackle some of the greatest challenges. However, one of the stark differences between the Army and academia is how the two train and equip people for the challenges they face in their job. (more…)

How we’re ensuring better care for older people with traumatic injuries

How we’re ensuring better care for older people with traumatic injuries
Originally published on the Imperial College Healthcare NHS Trust blog, consultant geriatrician Dr George Peck explains how the Trust is ensuring better care for older patients, and how trauma medicine is evolving to meet changing needs.


Bringing geriatric expertise to trauma care

As a registrar working with consultant geriatrician Dr Michael Fertleman, I was increasingly called to the trauma ward to offer geriatric assessments to patients who struggled with multiple issues. Best practice is to give a patient with suspected frailty a comprehensive geriatric assessment within 72 hours, but the volume of patients we receive who qualify has grown so much that this cannot be done without having a consultant geriatrician embedded in the service full time.

As a result, I became the first geriatrician in London to run a dedicated, embedded service in the trauma department. I will sit in the multidisciplinary team meeting with trauma surgeons, go on joint ward rounds with them throughout the week, and see major trauma patients whenever I am needed. I also help look after our surgical rehabilitation ward, which is for patients who are stable but require a longer period in hospital to recover. It is very rewarding to be able to offer continuity of care to our older trauma patients. (more…)

Thinking outside the ice box: revolutionising pancreas transplantation

Karim Hamaoui provides an insight into an innovative solution for the organ donation shortage – a technique that allows the pancreas to be preserved for longer and for better function.


The pancreas responsible for producing one of the body’s most important hormones: insulin. Since the first pancreas transplant in 1966, this procedure has revolutionised the treatment of type 1 diabetes. To date, pancreas transplantation is the only definitive treatment to render patients free from daily insulin injections and provide a better quality of life for these patients.

A key problem in the UK and worldwide is the limited supply of organs available and suitable for transplantation. The majority of pancreases used for transplantation in the UK come from a person who has died, and whose relatives have given permission for them to become an organ donor. To meet demand, the criteria used to identify suitable donors can be expanded from ‘ideal’ to ‘extended’ criteria. Extended criteria donors can also be euphemistically referred to as donors with ‘medical complexities’. They are normally aged 60 years or older, or aged over 50 years but with at least two of the following conditions: high blood pressure history, degree of kidney impairment, cause of death from a stroke. Unfortunately, complications are more pronounced for these types of organs. (more…)